Navigation Links
IntegriChain Launches DNA: Dynamic NextGen Analytics(TM) Platform
Date:2/16/2010

PRINCETON, N.J., Feb. 16 /PRNewswire/ -- IntegriChain, Inc., a commercial insight provider supporting the pharmaceutical industry, announces the launch of its new DNA: Dynamic NextGen Analytics™ (DNA) platform. This powerful new analytic platform helps pharmaceutical manufacturers unlock the value of Direct Data through data integration, enrichment and guided analytics. Direct Data includes those data assets typically provided to the manufacturer as a function of other agreements such as fee for service, rebates, coupon programs and chargebacks.

"The pharmaceutical industry is swamped with data, both syndicated and direct. Yet answers to fundamental questions are still difficult to find. Newly emerging data sets including syndicated retail data are compounding the problem," states Kevin Leininger, IntegriChain's CEO. "Poor data quality, high cost, high latency and the historical ad-hoc nature of projects in our industry have created pressure for pharmaceutical executives. Pre-existing solutions have simply been inadequate to allow manufacturers to build a sufficient value proposition around what should be a widely leveraged, shared data asset."

IntegriChain's DNA platform has been built upon a SaaS architecture and scales to support dynamic analysis of a billion+ transaction volumes with minimal latency. The robust architecture, data warehousing and analytic capabilities of DNA can be accessed via a zero-footprint web interface, further reducing the total cost of ownership for IntegriChain's customers.

As part of the DNA: NextGen Analytics platform, IntegriChain is providing customers with a series of advanced analytical modules — DNA: Channel™, DNA: Chargeback Validation ® and DNA: Measurement of Retail Inventory™ — to maximize the value of Direct Data within multiple functions of the commercial pharmaceutical organization, including Trade Operations, Finance, Managed Markets and Brand Marketing. Through DNA: Channel, IntegriChain now offers the opportunity for customers to directly connect with trading partners, providing near real-time, on-line access to all EDI data streams. All of the analytics within the platform leverage IntegriChain's Enriched Channel Sales™, the company's unparalleled channel data enrichment service that brings full transparency and strong business value to traditionally redacted and, therefore, unusable channel data. The DNA platform will allow IntegriChain to rapidly deploy additional analytic modules as the pharmaceutical industry continues to evolve.

"DNA is a low latency platform that uses a customer's own data to quickly and inexpensively answer a whole host of questions critical to the new commercial model emerging in pharma. DNA solves manufacturers' inherent data challenges," noted Leininger.

DNA: Dynamic NextGen Analytics from IntegriChain is available now and is currently in production at IntegriChain's industry-leading clients, spanning small, medium and top-tier pharmaceutical manufacturers. IntegriChain offers a rapid deployment program that can have most manufacturers fully implemented in less than 90 days.

IntegriChain embraces the concept of guided analytics — a combination of cutting-edge business intelligence technology, advanced visualization, statistical tools and subject matter expertise. DNA: Dynamic NextGen Analytics is the only single source solution for collection, enrichment, query and advanced analytics of all Direct Data, providing 100 percent visibility to commercial demand in a low-latency business insight platform.

About IntegriChain

IntegriChain enables manufacturers to improve sales performance and total pipeline measurement by maximizing visibility to the down-stream channel. IntegriChain's DNA: Dynamic NextGen Analytics are transforming the role of channel data within key pharmaceutical application areas including product launch, sales reporting, sales forecasting and demand analysis. IntegriChain is a privately held, venture-backed company headquartered in Princeton, New Jersey, and has been deployed across a growing number of pharmaceutical manufacturers including six of the top ten global leaders in the pharmaceutical industry.

SOURCE IntegriChain, Inc.

RELATED LINKS
http://www.integrichain.com

'/>"/>

SOURCE IntegriChain, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
2. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
3. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
4. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
5. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
6. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
7. Premier Micronutrient Launches Supplement for Hearing Health
8. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
9. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
10. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control
11. PositiveFriends.com Launches STD Social Networking Site Balancing Dating with Online Support Features
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... York , May 23, 2016 ... report titled, " Exocrine Pancreatic Insufficiency Market - Global ... - 2023 ." According to the report, the exocrine ... CAGR of 8.3% from 2015 to 2023 to reach ... (EPI) is a condition characterized by the deficiency of ...
(Date:5/23/2016)... -- Non-invasive diagnostic test realizes the potential ... to be presented at Yissum’s booth, at IATI-BIOMED 2016 ... of the Hebrew University of Jerusalem announced today ... Ventures MKI, the technology investment arm of Morris Kahn ... for early detection of multiple diseases by analyzing circulating ...
(Date:5/23/2016)... 2016   Purdue Pharma L.P.  today announced ... with Egalet Corporation and Acura Pharmaceuticals, Inc. that ... the agreement the companies will exchange valuable patent ... companies to develop and sell several opioid pain ... reflects the commitment of Purdue Pharma to seek ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... ... Loma Linda University Health (LLUH) has officially broken ground on the hospital ... people looked on as the shovels hit the dirt at the community groundbreaking event ... the program, Richard H. Hart, MD, DrPH, president, LLUH, recapped the history of the ...
(Date:5/24/2016)... ... ... Boyd Industries, a leading supplier of dental chairs and cabinetry , ... pediatric dentistry , at AAPD 2016, the annual conference and trade show of the ... Unit keeps dental hand pieces and other anxiety-provoking pieces of the dental delivery system ...
(Date:5/24/2016)... ... May 24, 2016 , ... A newly released report reveals that ... access to trusted resources, both in face-to-face interactions and online. In “Heard, Not Judged ... concluded that the creative use of mobile digital devices can be an effective tool ...
(Date:5/24/2016)... ... May 24, 2016 , ... Growing in popularity, more and more people continue ... available and easily accessible. Whether someone chooses to cut gluten out of their life ... King Kullen Grocery stocks their shelves with many different gluten-free products all year round. ...
(Date:5/24/2016)... ... 24, 2016 , ... American Gene Technologies International, Inc ... its board of directors. Otterstatter is co-founder, president and CEO of Preventice, ... that lead to broad-based healthcare solutions. , “Jon knows how to create disruptive ...
Breaking Medicine News(10 mins):